Rezvan Ameli
Clinical Psychologist at the National Institutes of Health (NIH)
Data updated
Research Footprint
Rezvan Ameli appears in 5 tracked papers (2014–2023), most studied alongside Ketamine and Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Anxiety Disorders.
Most-cited paper: Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety (283 citations).
Frequent co-authors: Carlos Zarate, David Luckenbaugh and Mark John Niciu.
Background & Research
Rezvan Ameli, PhD, is a clinical psychologist and mindfulness instructor at the NIH Clinical Center, where she has worked as a clinician, researcher, writer, and teacher for more than 20 years. Her earlier work focused on mindfulness, stress reduction, and psychological well-being, and she has held academic positions at Yale University, the University of Connecticut, and Howard University. More recently, she has coauthored studies on ketamine and psilocybin-assisted therapy in depression, bipolar depression, and cancer-related distress.
Key Impact
She has contributed to foundational NIH-HEALS and psychedelic-assisted therapy research in cancer patients, helping measure and characterize psycho-social-spiritual change and suicidal ideation outcomes in rapid-acting antidepressant studies.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Rezvan Ameli's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Rezvan Ameli is associated with.
National Institutes of Health (NIH)
U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Sunstone Therapies
A U.S. clinical research and care organization focused on psychedelic-assisted therapy delivery in structured clinical settings.
View stakeholder →